ZD6474

ZD6474 (also known as Vandetanib or Caprelsa) is a small molecule inhibitor used in the treatment of certain types of cancer. It is a dual inhibitor of EGFR and VEGFR2.

Mechanism of Action

ZD6474 works by inhibiting the tyrosine kinases associated with the EGFR and VEGFR2 receptors. This inhibition prevents the activation of these receptors, thereby reducing the growth and proliferation of cancer cells.

Uses

ZD6474 is used in the treatment of medullary thyroid cancer and non-small cell lung cancer. It may also be used in the treatment of other types of cancer, as determined by a healthcare provider.

Side Effects

Common side effects of ZD6474 include nausea, diarrhea, and rash. More serious side effects may include QT prolongation, interstitial lung disease, and hepatotoxicity.

History

ZD6474 was developed by AstraZeneca and was first approved for use in the United States in 2011.

See Also

• List of cancer drugs
• List of EGFR inhibitors
• List of VEGFR inhibitors

ZD6474 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski